Form 4: Alnylam EVP Sells Shares for Tax & 10b5-1 Plan

Alnylam Pharmaceuticals EVP Chief R&D, Pushkal Garg, reported sales of common stock totaling 4,713 shares for tax obligations and under a pre-arranged trading plan.

Summary

• Pushkal Garg, EVP Chief R&D of Alnylam Pharmaceuticals, Inc. (ALNY), reported sales of common stock.
• A total of 4,713 shares were disposed of across transactions on March 4 and March 5, 2026.
• Sales on March 4, 2026, totaling 2,309 shares, were primarily 'sell-to-cover' for minimum statutory tax withholding obligations upon the vesting of restricted stock units.
• Sales on March 5, 2026, totaling 2,404 shares, were executed pursuant to a Rule 10b5-1(c) trading plan adopted on November 20, 2025.
• The weighted average sales prices for these transactions ranged from $318.27 to $326.40 per share.
• Following these transactions, Pushkal Garg directly beneficially owns 18,693 shares of common stock.
• Indirect beneficial ownership includes 431 shares in a managed account and 250 shares held in a trust, with beneficial ownership of the trust shares disclaimed for Section 16 purposes.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine insider sales for tax purposes and under a pre-arranged trading plan, not indicative of a change in company fundamentals or executive sentiment.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing, as it is solely focused on reporting insider transactions.

Industry Context

StockSavvy.ai notes that routine insider sales, particularly those for tax obligations or pre-scheduled 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors. These transactions typically do not reflect a change in management's confidence in the company's long-term prospects but rather personal financial planning or tax management.

Comparison to Industry Standards

• Insider transactions for tax-related 'sell-to-cover' provisions are standard practice across all industries, including biotechnology, when restricted stock units vest.
• The use of Rule 10b5-1 trading plans is a common corporate governance practice among executives at publicly traded companies like Pfizer, Moderna, and Johnson & Johnson, designed to allow insiders to sell shares without concerns of insider trading by pre-scheduling transactions.

Stakeholder Impact

• Minimal direct impact on shareholders as these are routine insider transactions for tax and pre-planned purposes, not signaling a shift in company strategy or performance.

Key Dates

Keywords

Alnylam Pharmaceuticals, ALNY, Insider Trading, Form 4, Stock Sale, Pushkal Garg, Executive Compensation, 10b5-1 Plan, Biotechnology, Pharmaceuticals